Denied

No. 16-360

Mylan Pharmaceuticals Inc., et al. v. Acorda Therapeutics Inc., et al.

from the United States Court of Appeals for the Federal Circuit

See other cases from the Federal Circuit.

Docket Entries

Petition DENIED. Justice Alito took no part in the consideration or decision of this petition.

DISTRIBUTED for Conference of January 6, 2017.

Rescheduled.

Reply of petitioners Mylan Pharmaceuticals, et al. filed. (Distributed)

DISTRIBUTED for Conference of January 6, 2017.

Brief of respondents Acorda Therapeutics, Inc. and Alkermes Pharma Ireland Limited in opposition filed.

Brief of respondent AstraZeneca AB in opposition filed.

Brief amicus curiae of Generic Pharmaceutical Association filed.

Order extending time to file response to petition to and including November 21, 2016, for all respondents.

Consent to the filing of amicus curiae briefs, in support of either party or of neither party, received from counsel for the respondents Acorda Therapeutics, Inc., and Pharma Ireland Limited.

Petition for a writ of certiorari filed. (Response due October 21, 2016)

Parties

Mylan Pharmaceuticals, et al., Petitioner, represented by Roy T. Englert, Jr.

Acorda Therapeutics, Inc. and Alkermes Pharma Ireland Limited, Respondent, represented by Theodore B. Olson

AstraZeneca AB, Respondent, represented by Kannon K. Shanmugam

Amici Curiae

Generic Pharmaceutical Association, Amicus Curiae, represented by James H. Wallace Jr.

 
Last updated: March 29, 2017